NCT00190723已完成2 期
A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 2
- 主要终点
- To establish data regarding the anti-tumor activity of LY317615 in patients with recurrent high-grade gliomas.
研究概览
简要总结
- The safety of LY317615 and any side effects that might be associated with the drug.
- Whether LY317615, can help patients with brain tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •You must be at least 18 years old
- •You must have been diagnosed with a recurrent brain tumor by MRI or CT scan
- •You must be able to swallow the LY317615 tablets
排除标准
- •You are a woman who is pregnant or breastfeeding
- •In view of your doctor, you have significant heart, liver, kidney, or psychiatric disease
结局指标
主要结局
To establish data regarding the anti-tumor activity of LY317615 in patients with recurrent high-grade gliomas.
次要结局
- To obtain preliminary information regarding the spectrum of toxicities of LY317615 administered to patients with recurrent high-grade gliomas
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.Non-Hodgkin's LymphomaNCT00042666Eli Lilly and Company55
已完成
1 期
A Study of LY3866288 in Healthy ParticipantsHealthyNCT06641037Eli Lilly and Company15
终止
1 期
A Study of LY3526318 in Healthy ParticipantsHealthyNCT03977974Eli Lilly and Company76
已完成
1 期
A Study of LY3361237 in Participants With Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT03933943Eli Lilly and Company28
已完成
1 期
A Study of LY3361237 in Participants With PsoriasisPsoriasisNCT04975295Eli Lilly and Company21